<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02940418</url>
  </required_header>
  <id_info>
    <org_study_id>T1DM.UJCTC</org_study_id>
    <nct_id>NCT02940418</nct_id>
  </id_info>
  <brief_title>Use of Stem Cells in Diabetes Mellitus Type 1</brief_title>
  <official_title>The Use of Mesenchymal Stromal Cells (MSC) in Type 1 Diabetes Mellitus in Adult Humans: Phase I Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sophia Al-Adwan</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Jordan</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Allogenic adipose derived mesenchymal stem cells will be injected into patients newly
      diagnosed with type 1 Diabetes Mellitus
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Adipose derived mesenchymal stem cells (ASCs) are to be collected from blood group O donor,
      cells will be passaged to passage 5.

      Before release the sample will be subject to our release criteria which include: testing for
      any bacterial or fungal growth as well as endotoxin and mycoplasma. All these tests must be
      negative. In addition the cell count and viability (must be more than 80%) are done before
      release. Surface markers documentation is done on the cells before release using flow
      cytometry.

      The cells should be infused within 2 hours of release. The dose to is to be repeated after 6
      months of a total of two doses in patients. Tests and follow up are to be one at week 12, 24
      and 36 when the study is stopped.

      These cells will be injected intravenously into patients newly diagnosed with type 1 Diabetes
      Mellitus.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 19, 2017</start_date>
  <completion_date type="Anticipated">July 2018</completion_date>
  <primary_completion_date type="Anticipated">January 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety of using allogenic ASC assessed by any adverse events</measure>
    <time_frame>6 months</time_frame>
    <description>Patients will be assessed for any adverse events as a result of the injection.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Diabetes Mellitus Type 1</condition>
  <arm_group>
    <arm_group_label>Dose 1 mil/kg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Adipose mesenchymal cells with bone marrow mononuclear cells.
Two doses with a 6 month interval of allogenic Adipose mesenchymal cells +1 mil/kg of autologous bone marrow mononuclear cells will be injected intravenously.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose 10 mil/kg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Adipose mesenchymal cells with bone marrow mononuclear cells.
Two doses with a 6 month interval of allogenic Adipose mesenchymal cells +10 mil/kg of autologous bone marrow mononuclear cells will be injected intravenously.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Adipose mesenchymal cells with bone marrow mononuclear cells</intervention_name>
    <description>Allogenic adipose-derived mesenchymal cells with autologous bone marrow mononuclear cells will be injected.</description>
    <arm_group_label>Dose 1 mil/kg</arm_group_label>
    <arm_group_label>Dose 10 mil/kg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Adult Patients with Type 1 Diabetes Mellitus.

          2. Age from 18 years to 35 years either gender.

          3. Duration of disease: not exceeding 3 years unless C-peptide is not less than 0.5 ng/ml

          4. C-Peptide at inclusion base line should not be less than 0.5 ng/ml

          5. No clinical evidence of renal, retinal, vascular or skin complications

          6. Body Mass Index not exceeding 30

          7. Any HbA1c

          8. At least one positive antibody either anti-Glutamic Acid Decarboxylase-65 or
             Insulinoma-Associated-2 Autoantibodies (anti-1A2)

          9. Informed Consent by patient

        Exclusion Criteria:

          1. Age less than 18 years and more than 35 years

          2. Pregnancy

          3. Married women or women expected to be married within the study period

          4. History of allergy, Cancer, bronchial asthma, liver disease or hepatitis

          5. Diabetic coma or pre-coma current or recent within the last 2 months

          6. C-Peptide less than 0.5 ng/ml

          7. Disease duration more than 3 yrs.

          8. Complication mentioned in 5 above in inclusion

          9. Non-consenting patient or withdrawal of consent.

         10. Bleeding disorders
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Abdallah Awidi, MD</last_name>
    <role>Study Director</role>
    <affiliation>Cell Therapy Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Hanan D. Jafar, PhD</last_name>
    <phone>00962798871087</phone>
    <email>hanan.jafar@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Cell Therapy Center</name>
      <address>
        <city>Amman</city>
        <zip>11942</zip>
        <country>Jordan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Abdalla Awidi, MD</last_name>
      <phone>0096265355000</phone>
      <phone_ext>23960</phone_ext>
      <email>abdalla.awidi@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Jordan</country>
  </location_countries>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 19, 2016</study_first_submitted>
  <study_first_submitted_qc>October 19, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 20, 2016</study_first_posted>
  <last_update_submitted>May 3, 2017</last_update_submitted>
  <last_update_submitted_qc>May 3, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 8, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Jordan</investigator_affiliation>
    <investigator_full_name>Sophia Al-Adwan</investigator_full_name>
    <investigator_title>Biologist, PhD</investigator_title>
  </responsible_party>
  <keyword>Diabetes Mellitus</keyword>
  <keyword>Type 1</keyword>
  <keyword>Adipose derived mesenchymal stem cells</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

